- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of October 23
The Center for Biosimilars® recaps the top 5 stories in biosimilars news for the week of October 23.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 23.
Number 5: Novartis credits stronger-than-expected sales of its biosimilars for strong third-quarter net income.
Number 4: Etanercept has been shown to significantly reduce overall healthcare utilization for patients with rheumatoid arthritis, especially for patients who are highly compliant with therapy.
Number 3: New evidence suggests that anti—tumor necrosis factor agents could be repurposed to treat depression that is unresponsive to existing therapies.
Number 2: The FDA has released new educational materials on biosimilars. The resources, geared toward clinicians, include webinars, staff presentations, graphics, and sharable social media assets.
Number 1: The RAND corporation has released a new report on biosimilars, estimating that the United States could save $54 billion over the next 10 years by using biosimilars.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
